Search

Displaying results 5621 - 5630 of 6835 in total
  1. Drug

    GSK2798745

    go.drugbank.com/drugs/DB16033
    Investigational

    GSK2798745 is under investigation in clinical trial NCT03372603 (A Study to Assess the Effectiveness and Side Effects of GSK2798745 in Participants With Chronic Cough).

  2. Drug

    Vinorelbine

    go.drugbank.com/drugs/DB00361
    ApprovedInvestigational

    Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC) . It was initially approved in the USA in 1990's for the trea...

  3. Drug

    Subasumstat

    go.drugbank.com/drugs/DB16406
    Investigational

    Subasumstat is under investigation in clinical trial NCT03648372 (A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced

  4. Drug

    Dihydroetorphine

    go.drugbank.com/drugs/DB01450
    ExperimentalIllicit

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  5. Drug

    Imipramine oxide

    go.drugbank.com/drugs/DB13782
    Experimental

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  6. Drug

    Lofepramine

    go.drugbank.com/drugs/DB13411
    Experimental

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  7. Drug

    KAND567

    go.drugbank.com/drugs/DB16511
    Investigational

    KAND567, a small molecule, blocks the fractaline (CX3CL1) receptor, which mediates the immune system response to inflammation[L32908].

  8. Drug

    Mupadolimab

    go.drugbank.com/drugs/DB16488
    Investigational

    CPI-006 was investigated in clinical trials NCT03454451, NCT04464395, and NCT04734873 to evaluate its safety and efficacy.

  9. Drug

    Oxyphencyclimine

    go.drugbank.com/drugs/DB00383
    Approved

    Oxyphencyclimine is an anticholinergic drug (trade name Daricon) used in treating peptic ulcers.

  10. Drug

    Remibrutinib

    go.drugbank.com/drugs/DB16852
    ApprovedInvestigational

    Remibrutinib is a selective Bruton's tyrosine kinase inhibitor. The FDA approved remibrutinib on September 30, 2025 as the only oral, targeted treatment for chronic spontaneous urticaria. Bruton's tyrosine kinase plays a role in B cell r...